ClinicalTrials.gg
CompletedNCT01635764PIONEER (OLE)Updated Jan 24, 2018Results posted

Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa

A Phase 3 interventional study of adalimumab in Hidradenitis Suppurativa, sponsored by AbbVie (prior sponsor, Abbott). Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
508
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Hidradenitis Suppurativa by AbbVie — 2 open to participants now, 5 under way, 2 of them phase 3. Hidradenitis Suppurativa · AbbVie.

Enrollment
3rd of 11
508 · median 243
Started
2012
the only one that year
Phase 3
6 of 18
none open now
Registered
3rd of 18
by date

Among the 18 studies in Hidradenitis Suppurativa by AbbVie, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2012, is one of 6 in phase 3, and was the 3rd registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

2 of the 18 studies in Hidradenitis Suppurativa by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hidradenitis Suppurativa by AbbVie, or all of them as a file.
02

Study summary

The purpose of this study to evaluate the long term safety, tolerability and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa (HS).

Read the detailed description

HS is a painful, chronic skin disease characterized by recurrent inflamed nodules and abscesses, which may rupture to form fistulas and subsequent scarring. This study is an open-label extension study available to subjects who participated in a prior adalimumab study who meet all the inclusion and none of the exclusion criteria.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • hidradenitis suppurativa
  • open-label
  • acne inversa
  • PIONEER (OPEN-LABEL EXTENSION)
  • adalimumab
  • HS
  • acne
  • tumor necrosis factor
  • abscess
  • inflammatory nodule
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who previously participated in a prior Phase 3 AbbVie hidradenitis suppurativa (HS) study (M11-313 or M11-810) and:

    1. Completed the study; or
    2. Experienced a loss of response (LOR); or
    3. Experienced worsening or absence of improvement

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with any other anti-tumour necrosis factor (anti-TNF) therapy (e.g., infliximab, etanercept), or participation in an adalimumab trial other than a prior Phase 3 AbbVie HS study.
  • Subject received any oral antibiotic treatment for HS within 28 days prior to the Baseline visit, except for antibiotics permitted in a prior Phase 3 AbbVie HS study.
  • Subject received prescription topical therapies for the treatment of HS within 14 days prior to the Baseline visit of Study M12-555.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
508 participants (actual)

Study arms

  • Experimental
    Adalimumab Every Week

    Adalimumab 40 mg every week.

    Biological: adalimumab

Interventions

  • Biologicaladalimumab

    Adalimumab pre-filled syringe, administered by subcutaneous injection

    Also known as: Humira

06

What researchers measure

Primary outcomes

  1. Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit

    Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  2. Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit

    Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

  3. Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit

    Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

  4. Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit

    The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  5. Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit

    The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

  6. Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit

    The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

  7. Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population

    The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Baseline (in prior phase 3 study) to Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216

  8. Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations

    The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Baseline (in prior phase 3 study) to Entry of M12-555 and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

  9. Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population

    The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Baseline (in prior phase 3 study) to Entry of Period B in prior phase 3 study and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

  10. Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

    The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

  11. Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

    The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

  12. Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

    The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

  13. Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

    The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

  14. Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

    The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192

  15. Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

    The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

    Time frame: Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204

07

Results

Posted Sep 5, 2017

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab Every Week
Started508
Completed235
Not completed273
Withdrew: Adverse event46
Withdrew: Lack of efficacy76
Withdrew: Exceed protocol-specified interventions2
Withdrew: Protocol deviation1
Withdrew: Withdrew consent67
Withdrew: Lost to follow-up53
Withdrew: Other28

Outcome measures

PrimaryPercentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit

Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. Last Observation Carried Forward (LOCF): The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Number · percentage of participants
Percentage of Participants in the EW/EW/EW, EW/EOW/EW, and EW/PBO/EW Analysis Populations Achieving Clinical Response Per Hidradenitis Suppurativa Clinical Response (HiSCR) at Each Visit
percentage of participantsEW/EW/EWEW/EOW/EWEW/PBO/EW
Week 234.139.834.1
Week 438.641.140.2
Week 851.148.947.8
Week 1252.355.651.1
Week 1650.056.745.7
Week 2056.845.645.7
Week 2448.947.842.4
Week 3662.554.452.2
Week 4858.055.658.7
Week 6062.557.858.7
Week 7259.161.153.3
Week 8456.856.755.4
Week 9656.854.453.3
Week 10860.256.753.3
Week 12056.852.245.7
Week 13252.352.250.0
Week 14451.154.452.2
Week 15648.952.250.0
Week 16852.353.346.7
Week 18051.154.446.7
Week 19251.155.646.7
Week 20450.054.446.7
Week 21650.054.446.7
PrimaryPercentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit

Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Reported as:
Number · percentage of participants
Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit
percentage of participantsPBO/EW/EW
Entry of Period B26.1
Week 1254.4
Week 2457.9
Week 3657.0
Week 4860.5
Week 6057.0
Week 7250.0
Week 8450.0
Week 9653.5
Week 10852.6
Week 12053.5
Week 13256.1
Week 14451.8
Week 15652.6
Week 16855.3
Week 18054.4
Week 19253.5
Week 20453.5
PrimaryPercentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit

Clinical response per HiSCR defined as percent reduction from baseline of the prior phase 3 study in the abscess and inflammatory nodule ≥ 50% (AN50) with no increase in the abscess count and no increase in the draining fistula count. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Reported as:
Number · percentage of participants
Percentage of Participants in the PBO/PBO/EW Analysis Population Achieving Clinical Response Per HiSCR at Each Visit
percentage of participantsPBO/PBO/EW
Entry of M12-55519.5
Week 446.7
Week 851.6
Week 1248.4
Week 1857.4
Week 2455.7
Week 3660.7
Week 4854.9
Week 6055.7
Week 7254.9
Week 8454.9
Week 9657.4
Week 10854.9
Week 12052.5
Week 13254.1
Week 14451.6
Week 15650.8
Week 16851.6
Week 18051.6
Week 19251.6
PrimaryPercentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit

The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Number · percentage of participants
Percentage of Participants in the EW/EW/EW Analysis Population Who Achieved Abscess and Inflammatory Nodule (AN) Count of 0, 1, or 2 at Each Visit
percentage of participantsEW/EW/EW
Week 222.7
Week 428.4
Week 838.6
Week 1235.2
Week 1637.5
Week 2042.0
Week 2436.4
Week 3648.9
Week 4846.6
Week 6043.2
Week 7250.0
Week 8445.5
Week 9644.3
Week 10846.6
Week 12044.3
Week 13244.3
Week 14443.2
Week 15645.5
Week 16846.6
Week 18046.6
Week 19247.7
Week 20447.7
Week 21646.6
PrimaryPercentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit

The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Entry of M12-555, Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Reported as:
Number · percentage of participants
Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Who Achieved AN Count of 0, 1, or 2 at Each Visit
percentage of participantsEW/EOW/EWEW/PBO/EWPBO/PBO/EW
Entry of M12-55531.122.821.1
Week 435.634.844.3
Week 843.242.453.3
Week 1245.544.645.1
Week 1850.041.350.0
Week 2443.246.757.4
Week 3654.545.757.4
Week 4850.042.452.5
Week 6048.943.551.6
Week 7250.043.554.1
Week 8453.444.650.8
Week 9651.140.252.5
Week 10851.140.251.6
Week 12046.637.052.5
Week 13251.137.053.3
Week 14448.941.352.5
Week 15647.739.151.6
Week 16851.135.951.6
Week 18051.135.951.6
Week 19251.135.951.6
PrimaryPercentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit

The percentage of participants with AN counts lowered to 0, 1, or 2 at each visit. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Reported as:
Number · percentage of participants
Percentage of Participants in the PBO/EW/EW Analysis Population Who Achieved AN Count of 0, 1, or 2 at Each Visit
percentage of participantsPBO/EW/EW
Entry of Period B20.0
Week 1238.6
Week 2443.0
Week 3642.1
Week 4843.9
Week 6045.6
Week 7243.9
Week 8443.9
Week 9646.5
Week 10842.1
Week 12045.6
Week 13246.5
Week 14449.1
Week 15645.6
Week 16846.5
Week 18045.6
Week 19245.6
Week 20445.6
PrimaryModified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Baseline (in prior phase 3 study) to Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, and 216
Reported as:
Mean · units on a scale
Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EW/EW Analysis Population
units on a scaleEW/EW/EW
Week 2-18.0 ± 25.27
Week 4-21.0 ± 31.81
Week 8-22.8 ± 35.45
Week 12-23.9 ± 48.30
Week 16-26.6 ± 54.63
Week 20-32.1 ± 73.69
Week 24-36.6 ± 74.99
Week 36-41.6 ± 93.11
Week 48-42.2 ± 115.22
Week 60-41.9 ± 119.98
Week 72-43.2 ± 122.30
Week 84-42.8 ± 123.18
Week 96-43.2 ± 126.21
Week 108-43.2 ± 124.92
Week 120-43.4 ± 127.65
Week 132-42.5 ± 128.45
Week 144-42.4 ± 129.37
Week 156-40.7 ± 130.30
Week 168-41.5 ± 130.40
Week 180-41.8 ± 129.89
Week 192-41.9 ± 130.46
Week 204-41.4 ± 130.72
Week 216-41.4 ± 130.94
PrimaryModified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Baseline (in prior phase 3 study) to Entry of M12-555 and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Reported as:
Mean · units on a scale
Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations
units on a scaleEW/EOW/EWEW/PBO/EWPBO/PBO/EW
Entry of M12-555-23.1 ± 56.94-10.5 ± 56.740.2 ± 51.35
Week 4-30.2 ± 48.99-18.8 ± 56.52-16.2 ± 56.16
Week 8-34.9 ± 47.42-21.2 ± 63.26-24.8 ± 51.55
Week 12-34.8 ± 55.71-25.5 ± 57.92-26.2 ± 54.58
Week 18-35.9 ± 47.92-26.2 ± 60.59-32.3 ± 48.60
Week 24-37.1 ± 47.39-24.1 ± 61.52-33.5 ± 50.20
Week 36-37.1 ± 46.07-24.7 ± 63.81-33.6 ± 57.58
Week 48-37.5 ± 47.94-24.8 ± 63.21-30.2 ± 64.84
Week 60-34.8 ± 50.17-22.6 ± 65.06-31.7 ± 66.33
Week 72-35.4 ± 55.22-20.1 ± 64.52-31.8 ± 65.26
Week 84-36.6 ± 51.33-20.0 ± 66.02-29.5 ± 65.79
Week 96-34.0 ± 49.42-18.3 ± 65.14-29.0 ± 68.85
Week 108-34.0 ± 54.41-18.3 ± 66.88-28.4 ± 71.52
Week 120-31.8 ± 60.85-16.2 ± 66.82-28.3 ± 70.37
Week 132-35.1 ± 53.01-16.7 ± 66.87-28.8 ± 69.79
Week 144-35.1 ± 53.94-16.6 ± 67.30-28.6 ± 70.03
Week 156-34.7 ± 53.95-15.7 ± 67.09-28.0 ± 69.11
Week 168-35.6 ± 53.72-15.5 ± 67.40-28.7 ± 69.81
Week 180-35.6 ± 53.64-15.4 ± 67.39-28.7 ± 69.81
Week 192-35.6 ± 53.64-15.4 ± 67.39-28.7 ± 69.81
PrimaryModified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population

The Sartorius Scale is used to quantify the severity of HS. Points are awarded for 12 body areas (left and right axillae, left and right sub/inframammary areas, intermammary area, left and right buttocks, left and right inguino-crural folds, perianal area, perineal area, and other): points were awarded for nodules (2 points for each); abscesses (4 points); fistulas (4 points); scars (1 point); other findings (1 point); and longest distance between two lesions (2-6 points, 0 if no lesions); and if lesions are separated by normal skin (yes-0 points; no-6 points). The total Sartorius score is the sum of the 12 regional scores. Higher scores indicate greater severity of HS. A negative change indicates decrease in severity. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Baseline (in prior phase 3 study) to Entry of Period B in prior phase 3 study and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Reported as:
Mean · units on a scale
Modified Sartorius Score: Change From Baseline to Each Visit for Participants in the PBO/EW/EW Analysis Population
units on a scalePBO/EW/EW
Entry of Period B-18.0 ± 38.32
Week 12-43.2 ± 48.07
Week 24-43.0 ± 53.08
Week 36-49.5 ± 57.05
Week 48-47.1 ± 61.95
Week 60-46.2 ± 60.94
Week 72-44.5 ± 67.13
Week 84-46.8 ± 64.57
Week 96-45.5 ± 70.63
Week 108-45.0 ± 74.15
Week 120-45.9 ± 75.30
Week 132-44.4 ± 78.09
Week 144-45.4 ± 76.53
Week 156-46.0 ± 76.17
Week 168-46.1 ± 75.84
Week 180-45.8 ± 75.96
Week 192-45.8 ± 75.89
Week 204-45.9 ± 75.96
PrimaryPercentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

The Patient's Global Assessment of Skin Pain Numeric Rating Scale (NRS) was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the Patient's Global Assessment of Skin Pain (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Reported as:
Number · percentage of participants
Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
percentage of participantsEW/EW/EW
Week 247.6
Week 446.0
Week 844.4
Week 1242.9
Week 1646.0
Week 2050.8
Week 2454.0
Week 3658.7
Week 4854.0
Week 6052.4
Week 7254.0
Week 8452.4
Week 9649.2
Week 10854.0
Week 12050.8
Week 13246.0
Week 14454.0
Week 15652.4
Week 16852.4
Week 18052.4
Week 19252.4
PrimaryPercentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Reported as:
Number · percentage of participants
Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
percentage of participantsEW/EOW/EWEW/PBO/EWPBO/PBO/EW
Entry of M12-55540.021.922.6
Week 447.543.144.6
Week 845.247.651.8
Week 1241.354.051.8
Week 1847.650.855.4
Week 2442.947.654.2
Week 3649.247.655.4
Week 4847.650.856.6
Week 6047.650.850.6
Week 7247.642.950.6
Week 8450.846.048.2
Week 9650.855.648.2
Week 10850.842.950.6
Week 12042.947.645.8
Week 13241.347.648.2
Week 14441.350.847.0
Week 15639.746.049.4
Week 16841.349.248.2
Week 18041.349.248.2
Week 19241.349.248.2
PrimaryPercentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - at worst at each visit among participants with baseline skin pain NRS - at worst ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Reported as:
Number · percentage of participants
Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - At Worst at Each Visit Among Participants With Baseline Skin Pain NRS At Worst ≥ 3
percentage of participantsPBO/EW/EW
Entry of Period B31.6
Week 1251.6
Week 2455.3
Week 3655.8
Week 4853.2
Week 6058.4
Week 7264.9
Week 8463.6
Week 9662.3
Week 10855.1
Week 12056.4
Week 13253.8
Week 14455.1
Week 15651.3
Week 16857.7
Week 18057.7
Week 19256.4
Week 20457.7
PrimaryPercentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Weeks 2 (first dose of adalimumab in prior phase 3 study), 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Reported as:
Number · percentage of participants
Percentage of Participants in the EW/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
percentage of participantsEW/EW/EW
Week 256.0
Week 452.0
Week 848.0
Week 1246.0
Week 1640.0
Week 2050.0
Week 2446.0
Week 3658.0
Week 4856.0
Week 6056.0
Week 7256.0
Week 8456.0
Week 9654.0
Week 10850.0
Week 12048.0
Week 13256.0
Week 14456.0
Week 15658.0
Week 16856.0
Week 18056.0
Week 19256.0
PrimaryPercentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Entry of M12-555, and Weeks 4, 8, 12, 18, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, and 192
Reported as:
Number · percentage of participants
Percentage of Participants in the EW/EOW/EW, EW/PBO/EW, and PBO/PBO/EW Analysis Populations Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
percentage of participantsEW/EOW/EWEW/PBO/EWPBO/PBO/EW
Entry of M12-55543.637.731.9
Week 449.046.861.8
Week 846.255.861.8
Week 1239.659.658.8
Week 1845.359.663.2
Week 2439.653.854.4
Week 3645.348.158.8
Week 4847.251.958.8
Week 6043.453.855.9
Week 7247.259.655.9
Week 8449.148.152.9
Week 9647.257.757.4
Week 10849.144.254.4
Week 12039.648.154.4
Week 13243.450.054.4
Week 14443.450.054.4
Week 15643.446.255.9
Week 16843.448.154.4
Week 18043.448.154.4
Week 19243.448.154.4
PrimaryPercentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3

The NRS was used to assess the worst skin pain and the average skin pain due to HS. Ratings for the 2 items range from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The assessments were completed on a daily diary by participants before they went to bed and responded to the items based on a recall period of the "last 24 hours." The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the NRS (NRS30) - on average at each visit among participants with baseline skin pain NRS - on average ≥ 3 are presented. Weekly averages of daily assessments were analyzed. LOCF: The last completed evaluation from the previous visit was carried forward to impute missing data at later visits.

Time frame:
Entry of Period B in prior phase 3 study, Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, and 204
Reported as:
Number · percentage of participants
Percentage of Participants in the PBO/EW/EW Analysis Population Achieving Skin Pain NRS30 - On Average at Each Visit Among Participants With Baseline Skin Pain NRS On Average ≥ 3
percentage of participantsPBO/EW/EW
Entry of Period B30.6
Week 1259.2
Week 2461.0
Week 3661.7
Week 4853.3
Week 6060.0
Week 7258.3
Week 8460.0
Week 9661.7
Week 10862.3
Week 12062.3
Week 13259.0
Week 14460.7
Week 15655.7
Week 16862.3
Week 18062.3
Week 19260.7
Week 20462.3

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 225 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
All Adalimumab—99/508 (19.5%)349/508 (68.7%)
Most frequent serious events
Showing 10 of 90
Most frequent serious events
EventAll Adalimumab
HIDRADENITISSkin and subcutaneous tissue disorders29/508
PNEUMONIAInfections and infestations3/508
OBESITYMetabolism and nutrition disorders3/508
ANGINA PECTORISCardiac disorders2/508
PALPITATIONSCardiac disorders2/508
CHOLELITHIASISHepatobiliary disorders2/508
APPENDICITISInfections and infestations2/508
CELLULITISInfections and infestations2/508
PILONIDAL CYSTInfections and infestations2/508
POSTOPERATIVE WOUND INFECTIONInfections and infestations2/508
Most frequent other events
Showing 10 of 16
Most frequent other events
EventAll Adalimumab
HIDRADENITISSkin and subcutaneous tissue disorders125/508
NASOPHARYNGITISInfections and infestations92/508
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations84/508
HEADACHENervous system disorders80/508
INFLUENZAInfections and infestations40/508
URINARY TRACT INFECTIONInfections and infestations40/508
ARTHRALGIAMusculoskeletal and connective tissue disorders38/508
BRONCHITISInfections and infestations37/508
DIARRHOEAGastrointestinal disorders33/508
BACK PAINMusculoskeletal and connective tissue disorders33/508

Baseline characteristics

Baseline characteristics provided by reporting groups defined by treatment received in the prior phase 3 studies, plus adalimumab every week (EW) received in M12-555. Baseline defined as the last measurement prior to the first dose of study drug in the prior phase 3 study (M11-810 or M11-310 for baseline characteristics.

Age, Continuous
Age, Continuous(years)EW/EW/EWEW/EOW/EWEW/PBO/EWPBO/EW/EWPBO/PBO/EWTotal
Mean35.5 ± 10.2736.1 ± 10.5036.5 ± 11.0638.5 ± 11.9237.0 ± 12.2836.8 ± 11.35
Sex: Female, Male
Sex: Female, Male(Participants)EW/EW/EWEW/EOW/EWEW/PBO/EWPBO/EW/EWPBO/PBO/EWTotal
Female5660507983328
Male3230423640180
08

Study locations

No study locations are listed for this record.

09

References and documents

Related links

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Aug 2016, 52 months.

Results were first posted in Sep 2017, 1 year 1 month after primary completion.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's 52 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2012
First posted
Jul 10, 2012
StartActual
Apr 2012
Primary completionActual
Aug 2016
CompletionActual
Aug 2016
Results first posted
Sep 5, 2017
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01635764
Responsible party
Sponsor
First posted
Jul 10, 2012
Start date
Apr 2012
Primary completion
Aug 2016
Completion
Aug 2016
Results posted
Sep 5, 2017
Last update
Jan 24, 2018

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion